

George Sakoulas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5297763/george-sakoulas-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92 papers	3,322 citations	33 h-index	56 g-index
138 ext. papers	3,950 ext. citations	6.2 avg, IF	5.34 L-index

#	Paper	IF	Citations
92	Is the Success of Cefazolin plus Ertapenem in Methicillin-Susceptible Bacteremia Based on Release of Interleukin 1-beta?. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , aac0216621	5.9	2
91	Potent Activity of Ertapenem Plus Cefazolin Within Staphylococcal Biofilms: A Contributing Factor in the Treatment of Methicillin-Susceptible Endocarditis.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofac159	1	1
90	Approaching 65 Years: Is It Time to Consider Retirement of Vancomycin for Treating Methicillin-Resistant Endovascular Infections?. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofac137	1	1
89	Impact of Clopidogrel on Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: a National Retrospective Cohort Study.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , e0211721	5.9	2
88	Repurposed drugs block toxin-driven platelet clearance by the hepatic Ashwell-Morell receptor to clear bacteremia. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	8
87	Current Paradigms of Combination therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination and For Which Patients?. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	11
86	Ticagrelor Increases Platelet-Mediated Staphylococcus aureus Killing, Resulting in Clearance of Bacteremia. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1566-1569	7	6
85	Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized COVID-19 Patients with Mild Hypoxemia. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 1323-1330	6.2	9
84	Environmental conditions dictate differential evolution of vancomycin resistance in Staphylococcus aureus. <i>Communications Biology</i> , 2021 , 4, 793	6.7	6
83	Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab136	1	1
82	Vancomycin or Daptomycin for Outpatient Parenteral Antibiotic Therapy: Does It Make a Difference in Patient Satisfaction?. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab418	1	1
81	Intravenous Immunoglobulin Plus Methylprednisolone Mitigate Respiratory Morbidity in Coronavirus Disease 2019 2020 , 2, e0280		20
80	Genome Sequence Comparison of Staphylococcus aureus TX0117 and a Beta-Lactamase-Cured Derivative Shows Increased Cationic Peptide Resistance Accompanying Mutations in and. <i>Microbiology Resource Announcements</i> , 2020 , 9,	1.3	1
79	Distinct Subpopulations of Intravalvular Methicillin-Resistant Staphylococcus aureus with Variable Susceptibility to Daptomycin in Tricuspid Valve Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	4
78	Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series. <i>Respiration</i> , 2020 , 99, 1145-1153	3.7	12
77	264. Anti-platelet Therapy Significantly Reduces Inpatient Mortality in Patients with Staphylococcus aureus Bacteremia. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S131-S131	1	
76	255. Ticagrelor Aids Platelet-Mediated Clearance in a Refractory Staphylococcus aureus Endovascular Infection with Septic Emboli. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S126-S127	1	1

75	Multicenter Cohort of Patients With Methicillin-Resistant Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz538	1	30
74	Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1413-1418	11.6	12
73	Case Commentary: Imipenem/Cilastatin and Fosfomycin for Refractory Methicillin-Resistant Infection: a Novel Combination Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 65,	5.9	1
72	Synergistic Effects of Pulsed Lavage and Antimicrobial Therapy Against Biofilms in an Model. <i>Frontiers in Medicine</i> , 2020 , 7, 527	4.9	4
71	Mortality Risk Profiling of Staphylococcus aureus Bacteremia by Multi-omic Serum Analysis Reveals Early Predictive and Pathogenic Signatures. <i>Cell</i> , 2020 , 182, 1311-1327.e14	56.2	22
70	Antibiotics and Innate Immunity: A Cooperative Effort Toward the Successful Treatment of Infections. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa302	1	5
69	Interleukin (IL)-1 β and IL-10 Host Responses in Patients With Staphylococcus aureus Bacteremia Determined by Antimicrobial Therapy. <i>Clinical Infectious Diseases</i> , 2020 , 70, 2634-2640	11.6	10
68	Genetic Determinants Enabling Medium-Dependent Adaptation to Nafcillin in Methicillin-Resistant Staphylococcus aureus. <i>MSystems</i> , 2020 , 5,	7.6	6
67	Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	10
66	Proton-pump inhibitors do not influence clinical outcomes in patients with bacteremia. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819834273	4.7	1
65	Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	76
64	Avibactam Sensitizes Carbapenem-Resistant NDM-1-Producing Klebsiella pneumoniae to Innate Immune Clearance. <i>Journal of Infectious Diseases</i> , 2019 , 220, 484-493	7	11
63	Is a Reported Penicillin Allergy Sufficient Grounds to Forgo the Multidimensional Antimicrobial Benefits of β -Lactam Antibiotics?. <i>Clinical Infectious Diseases</i> , 2019 , 68, 157-164	11.6	18
62	Omadacycline for Acute Bacterial Skin and Skin Structure Infections. <i>Clinical Infectious Diseases</i> , 2019 , 69, S23-S32	11.6	19
61	Surprising synergy of dual translation inhibition vs. Acinetobacter baumannii and other multidrug-resistant bacterial pathogens. <i>EBioMedicine</i> , 2019 , 46, 193-201	8.8	13
60	Reduced Production of Bacterial Membrane Vesicles Predicts Mortality in ST45/USA600 Methicillin-Resistant Bacteremia. <i>Antibiotics</i> , 2019 , 9,	4.9	4
59	Reply to Kalil et al., "Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?". <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	1
58	Listeria monocytogenes endocarditis: case report, review of the literature, and laboratory evaluation of potential novel antibiotic synergies. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 468-478	14.3	12

57	Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 764-767	5.1	8
56	Humanized Exposures of a β -Lactam- β -Lactamase Inhibitor, Tazobactam, versus Non- β -Lactam- β -Lactamase Inhibitor, Avibactam, with or without Colistin, against <i>Acinetobacter baumannii</i> in Murine Thigh and Lung Infection Models. <i>Pharmacology</i> , 2018 , 101, 255-261	2.3	4
55	The Two-Component System AgrAC Displays Four Distinct Genomic Arrangements That Delineate Genomic Virulence Factor Signatures. <i>Frontiers in Microbiology</i> , 2018 , 9, 1082	5.7	10
54	Characterization of genetic changes associated with daptomycin nonsusceptibility in <i>Staphylococcus aureus</i> . <i>PLoS ONE</i> , 2018 , 13, e0198366	3.7	11
53	1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S412-S412	1	4
52	637. β -Lactam (BL) Antibiotics Promote an IL-1 β Response in Patients with <i>Staphylococcus aureus</i> Bacteremia (SaB). <i>Open Forum Infectious Diseases</i> , 2018 , 5, S232-S232	1	78
51	2390. Avibactam Sensitizes NDM <i>Klebsiella pneumoniae</i> to Innate Immune Killing by Human Cathelicidin LL-37, Serum, Neutrophils, and Platelets. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S712-S713 ¹		78
50	Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate <i>Staphylococcus aureus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 91, 363-370	2.9	10
49	Evidence To Support Continuation of Statin Therapy in Patients with <i>Staphylococcus aureus</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	12
48	Increased Endovascular <i>Staphylococcus aureus</i> Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1406-1412	11.6	32
47	Dissecting Out the Direct Impacts of Large-Scale Antimicrobial Stewardship Interventions on Clinical Outcomes: Can Confounding Be Overcome?. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1956-1957	11.6	
46	Interaction of Antibiotics with Innate Host Defense Factors against Serotype Newport. <i>MSphere</i> , 2017 , 2,	5	20
45	β -Lactamase Inhibitors Enhance the Synergy between β -Lactam Antibiotics and Daptomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	7
44	Classical β -Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant <i>Staphylococcus aureus</i> and Colistin against <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	12
43	Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent <i>Staphylococcus aureus</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 6609-6618	5.9	19
42	Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2014-21	5.1	30
41	Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR <i>Stenotrophomonas maltophilia</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1264-9	5.1	36
40	When sepsis persists: a review of MRSA bacteraemia salvage therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 576-86	5.1	47

39	Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β -Lactam-Daptomycin Synergy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 451-8	5.9	38
38	New Guidelines Endorse Old Recommendations for Invasive Enterococcal Infections. <i>Clinical Infectious Diseases</i> , 2016 , 63, 281-2	11.6	
37	Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2799-806	5.9	25
36	β -Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1738-43	5.1	75
35	Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens. <i>EBioMedicine</i> , 2015 , 2, 690-8	8.8	148
34	Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2428-31	5.9	14
33	Differential Effects of Penicillin Binding Protein Deletion on the Susceptibility of Enterococcus faecium to Cationic Peptide Antibiotics. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6132-9	5.9	3
32	Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 311-3	5.1	34
31	Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. <i>Pharmacotherapy</i> , 2015 , 35, 608-12	5.8	19
30	Clinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia. <i>Clinical Therapeutics</i> , 2015 , 37, 1443-1453.e2	3.5	28
29	Reply to Eschenauer et al. <i>Clinical Infectious Diseases</i> , 2015 , 60, 671-2	11.6	1
28	In vitro activity of daptomycin in combination with β -lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4279-88	5.9	36
27	Comment on: Failure of combination therapy with daptomycin and synergistic cefttriaxone for enterococcal endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1272-3	5.1	1
26	Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. <i>Journal of Molecular Medicine</i> , 2014 , 92, 139-49	5.5	93
25	Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. <i>Clinical Therapeutics</i> , 2014 , 36, 1303-16	3.5	47
24	Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. <i>Clinical Therapeutics</i> , 2014 , 36, 1317-33	3.5	118
23	Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: role in cross-resistance between daptomycin and host defense antimicrobial peptides. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7462-7	5.9	47
22	Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. <i>Clinical Infectious Diseases</i> , 2014 , 59, 1455-61	11.6	45

21	Potent synergy of ceftobiprole plus daptomycin against multiple strains of <i>Staphylococcus aureus</i> with various resistance phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3006-10	5.1	36
20	Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant <i>Enterococcus faecium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1494-500	5.9	67
19	Human cathelicidin LL-37 resistance and increased daptomycin MIC in methicillin-resistant <i>Staphylococcus aureus</i> strain USA600 (ST45) are associated with increased mortality in a hospital setting. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 2172-4	9.7	11
18	1044Efficacy of Ceftolozane/Tazobactam vs Levofloxacin in the Treatment of Complicated Urinary Tract Infections (cUTI) caused by Levofloxacin-resistant Pathogens: Results from the ASPECT-cUTI Trial. <i>Open Forum Infectious Diseases</i> , 2014 , 1, S306-S306	1	1
17	Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2148-54	5.1	45
16	Treatment of high-level gentamicin-resistant <i>Enterococcus faecalis</i> endocarditis with daptomycin plus ceftaroline. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 4042-5	5.9	50
15	Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant <i>Enterococcus faecium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 838-44	5.9	132
14	Novel bacterial metabolite merochlorin A demonstrates in vitro activity against multi-drug resistant methicillin-resistant <i>Staphylococcus aureus</i> . <i>PLoS ONE</i> , 2012 , 7, e29439	3.7	58
13	Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with <i>Staphylococcus aureus</i> bacteremia. <i>Journal of Infectious Diseases</i> , 2012 , 206, 1604-11	7	76
12	High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. <i>Pharmacotherapy</i> , 2011 , 31, 527-36	5.8	112
11	Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible <i>Staphylococcus aureus</i> bacteremia. <i>BMC Infectious Diseases</i> , 2011 , 11, 279	4	169
10	Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant <i>Staphylococcus aureus</i> : role of enhanced daptomycin binding. <i>Clinical Infectious Diseases</i> , 2011 , 53, 158-63	11.6	197
9	Clinical outcomes of patients receiving daptomycin for the treatment of <i>Staphylococcus aureus</i> infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. <i>Clinical Therapeutics</i> , 2009 , 31, 1936-45	3.5	44
8	Evaluation of endocarditis caused by methicillin-susceptible <i>Staphylococcus aureus</i> developing nonsusceptibility to daptomycin. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 220-4	9.7	41
7	Daptomycin for soft tissue infection and neutropenia in a myelogenous leukemia patient who failed prior vancomycin therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 813-5	0.6	4
6	Perspectives on Daptomycin resistance, with emphasis on resistance in <i>Staphylococcus aureus</i> . <i>Clinical Infectious Diseases</i> , 2007 , 45, 601-8	11.6	142
5	Daptomycin nonsusceptibility in <i>Staphylococcus aureus</i> with reduced vancomycin susceptibility is independent of alterations in MprF. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 2223-5	5.9	68
4	Daptomycin in the treatment of bacteremia. <i>American Journal of Medicine</i> , 2007 , 120, S21-7	2.4	41

3	Induction of daptomycin heterogeneous susceptibility in <i>Staphylococcus aureus</i> by exposure to vancomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 1581-5	5.9	226
2	Adaptation of methicillin-resistant <i>Staphylococcus aureus</i> in the face of vancomycin therapy. <i>Clinical Infectious Diseases</i> , 2006 , 42 Suppl 1, S40-50	11.6	125
1	Reduced susceptibility of <i>Staphylococcus aureus</i> to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (<i>agr</i>) function. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 2687-92	5.9	144